首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1372743

基於腫瘤學的體內CRO 市場- 全球行業規模、佔有率、趨勢、機會和預測，2018-2028 年按適應症（血癌、實體瘤）、按模型（同基因模型、患者衍生異種移植、異種移植）、按地區和競賽

Oncology Based In-vivo CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft), By Region and Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022 年全球化學品即服務市場價值為 12.4 億美元，預計在預測期內將大幅成長，預計年複合成長率 (CAGR) 為 8.29%，預計到 2028 年將達到 109.2 億美元。

主要市場促進因素

市場概況
預測期	2024-2028
2022 年市場規模	12.4億美元
2028 年市場規模	20億美元
2023-2028 年年複合成長率	8.29%
成長最快的細分市場	實體腫瘤
最大的市場	北美洲

癌症盛行率上升

癌症發生率的不斷上升推動基於腫瘤學的體內合約研究組織（CRO）市場進入了一個充滿活力的成長階段。隨著癌症繼續在全球範圍內產生令人震驚的影響，對快速、精確的解決方案的需求不斷增加，從而刺激了研究和開發活動的激增。這種激增反過來又推動了對體內 CRO 提供的專業服務的需求。隨著癌症生物學和治療方式的複雜性不斷發展，製藥和生物技術公司越來越依賴這些 CRO 進行複雜的臨床前和臨床研究。癌症研究的複雜性需要採用多學科方法，而體內 CRO 擅長提供必要的工具、專業知識和資源來加速創新療法的開發。隨著個人化醫療的發展，根據個別基因圖譜客製化治療方法需要這些 CRO 提供複雜的研究技術。此外，隨著公司尋求簡化營運和提高效率，將新療法推向市場的競爭推動了外包趨勢。在基因組學、成像技術和資料分析快速發展的背景下，體內 CRO 在促進突破性發現方面發揮著不可或缺的作用。最終，癌症病例的激增不僅增加了對有效治療的需求，也成為基於腫瘤的體內CRO市場擴張和多元化的強大催化劑，將其推向戰鬥最前沿的關鍵地位對抗這種可怕的疾病。

癌症研究進展

不斷發展的癌症研究格局正在對基於腫瘤學的體內合約研究組織 (CRO) 市場的成長軌跡產生深遠的影響。隨著我們對癌症生物學、遺傳學和治療機制理解的每一步進步，對體內 CRO 提供的高度專業化研究服務的需求激增。免疫療法、標靶療法和精準醫學等領域的進步已經改變了腫瘤學領域，需要更複雜和量身定做的研究。體內 CRO 擁有進行與這些突破一致的複雜臨床前和臨床研究所需的專業知識和尖端技術。隨著新的治療途徑的出現，製藥和生物技術公司擴大求助於這些 CRO，以加快藥物開發過程並確保其療法的安全性和有效性。遺傳學、腫瘤微環境和治療反應之間錯綜複雜的相互作用要求採用全面、多維的研究方法，而體內 CRO 已準備好熟練地履行這一職責。此外，處於創新癌症治療前沿的競爭動力促使公司將研究活動外包給專業合作夥伴，有助於 CRO 市場的擴張。在科學快速進步的時代，癌症研究的進步與基於腫瘤學的體內 CRO 市場的成長之間的共生關係，有望在對抗癌症的鬥爭中開闢一條變革性的道路。

主要市場挑戰

癌症研究的複雜性

癌症研究的複雜性是阻礙基於腫瘤學的體內合約研究組織（CRO）市場成長的巨大障礙。癌症類型的多樣性、複雜的遺傳變異和不斷發展的治療範式帶來的多方面挑戰需要很少有人能夠提供的專業知識水平。進行準確、全面的體內研究來反映生物體內癌症的複雜現實需要複雜的方法和設備，這可能會導致 CRO 及其客戶的資源緊張。此外，需要跟上快速發展的科學發現，這又增加了一層複雜性。確保體內研究有效捕捉遺傳因素、腫瘤微環境和治療反應之間的複雜相互作用，需要採取多維方法，不僅需要尖端技術，還需要對癌症生物學的深入了解。因此，癌症研究的複雜性可能會限制專家庫、增加成本和延長專案時間，從而阻礙體內 CRO 市場的成長，從而強調了該領域持續創新和合作的迫切需求。

成本高

基於腫瘤學的體內合約研究組織（CRO）服務的成本飆升對市場的擴張構成了重大障礙。進行全面的體內研究需要先進的設備、熟練的人員和大量的資源，從而導致專案成本增加。這些費用可能會阻礙規模較小的製藥和生物技術公司以及預算有限的研究機構獲得體內 CRO 提供的專業知識和服務。此外，高成本還可能導致服務價格上漲，可能使某些客戶無法負擔。這種財務壓力可能會限制研發工作，減慢藥物發現的步伐，並限制該行業容納更廣泛項目的能力。因此，解決高成本問題對於培養一個更容易獲得和充滿活力的體內腫瘤學 CRO 市場至關重要，使不同的實體能夠利用所需的專業能力來促進我們對癌症的理解和治療。

主要市場趨勢

個人化醫療

個人化醫療的典範轉移正在對基於腫瘤學的體內合約研究組織（CRO）市場的成長軌跡產生深遠的影響。隨著醫學科學越來越認知到個別患者對治療反應的獨特遺傳和分子特徵，對高度客製化的研究和臨床前研究的需求激增。體內 CRO 處於這一變革趨勢的前沿，能夠創建高度模仿患者遺傳特徵的動物模型。這些模型可以精確評估潛在的療法，並預測其在特定患者群體中的有效性和潛在的副作用。遺傳因素、腫瘤微環境和治療反應之間錯綜複雜的相互作用需要細緻的研究方法，而體內 CRO 擁有執行此類研究所需的專業知識和尖端技術。為了開發對每位患者最有效且毒性最小的治療方法，製藥和生物技術公司越來越依賴體內 CRO 進行研究，以彌補臨床前研究和臨床試驗之間的差距。隨著個人化醫療的發展勢頭，體內 CRO 在塑造腫瘤學研究和治療開發格局方面的戰略作用變得越來越明顯，鞏固了它們對精準癌症護理進步的關鍵貢獻。

數位化和數據分析

數位化和資料分析的快速整合正在對基於腫瘤學的體內合約研究組織 (CRO) 市場的成長軌跡產生變革性影響。隨著癌症研究日益由資料驅動，體內 CRO 正在利用先進技術來提高研究的效率、準確性和深度。即時監測、高解析度成像和複雜的資料分析工具可以全面了解癌症生物學、治療反應和疾病進展。這場數位革命使研究人員能夠從複雜的資料集中提取有意義的見解，識別以前難以捉摸的微妙模式和相關性。配備這些功能的體內 CRO 可以全面了解潛在療法如何在分子和細胞層面上與生物體相互作用，為藥物開發過程中做出更明智的決策鋪平道路。此外，數位工具的整合促進了遠端監控和協作，使研究人員能夠跨越地理邊界進行研究。這不僅加快了研究進度，也為全球合作夥伴和客戶合作打開了大門。隨著腫瘤學研究對精確和數據豐富的見解的需求不斷增加，善於利用數位化和資料分析的體內CRO 準備推動我們對癌症的理解的進步，並推動更有效療法的開發，鞏固其在癌症研究中的關鍵作用。腫瘤學研究的動態景觀。

細分市場洞察

適應症見解

實體瘤領域到 2022 年將佔據 47.08% 的市場佔有率，在基於腫瘤的體內 CRO 市場中佔據主導地位，預計在未來幾年將繼續擴大。由於其普遍性和複雜性，實體瘤已成為基於腫瘤學的體內合約研究組織（CRO）市場的主導者。這些腫瘤的特徵是具有黏性的細胞團，佔癌症病例的很大一部分，從而推動了對體內 CRO 提供的專門研究服務的需求。鑑於實體腫瘤內基因突變、微環境因素和治療反應之間錯綜複雜的相互作用，體內 CRO 進行的臨床前研究對於評估潛在療法至關重要。隨著對實體瘤生物學和標靶治療的理解不斷進步，製藥和生物技術公司越來越依賴這些 CRO 進行全面研究，為臨床試驗設計和決策提供資訊。體內 CRO 在創建準確的動物模型和進行複雜分析方面的專業知識與實體瘤研究的複雜性相一致，使他們成為提高我們對抗這些可怕疾病的能力的關鍵貢獻者。

模型見解

2022年，基於腫瘤的體內CRO市場由Syngeneic細分市場主導，其收入佔有率最大，為70.82%。同基因模型因其在癌症研究中的特殊相關性和實用性而在基於腫瘤學的體內合約研究組織 (CRO) 市場中佔據主導地位。這些模型涉及將腫瘤細胞移植到具有完整免疫系統的同一物種動物體內，從而能夠研究腫瘤-免疫相互作用和免疫療法的評估。這種方法更準確地反映了人類對腫瘤免疫反應的複雜動態。隨著免疫療法作為癌症治療的突破性途徑受到關注，製藥和生物技術公司尋求在同基因模型方面具有專業知識的體內 CRO。這些 CRO 能夠評估新型免疫療法的功效和安全性、預測潛在副作用並最佳化治療策略。透過密切複製人類免疫系統對腫瘤的反應，同基因模型在推進免疫療法研究和塑造基於腫瘤學的 CRO 服務軌跡方面發揮關鍵作用。

區域洞察

北美地區已成為基於腫瘤的體內 CRO 市場的領導者，2022 年收入佔有率將達到 37%。

Chemical management services (CMS) represent a business framework where consumers opt for chemical services rather than direct chemical procurement. CMS plays a crucial role in assisting manufacturers in streamlining and enhancing the efficiency of their chemical management processes. Various sectors benefit from the chemical-as-a-service model, including agriculture and fertilizer, water treatment and purification, metal parts cleaning, paint and coatings, industrial cleaning, industrial gases, and other related domains.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 1.24 Billion
Market Size 2028	USD 2.00 Billion
CAGR 2023-2028	8.29%
Fastest Growing Segment	Solid Tumor
Largest Market	North America

Rising Prevalence of Cancer

The relentless rise in cancer incidence has propelled the oncology-based in vivo Contract Research Organization (CRO) market into a dynamic phase of growth. As cancer continues to exert an alarming global impact, there is an escalating demand for swift and precise solutions, spurring a surge in research and development activities. This surge, in turn, fuels the need for specialized services provided by in vivo CROs. With the intricacies of cancer biology and treatment modalities constantly evolving, pharmaceutical and biotechnology companies increasingly rely on these CROs to conduct intricate preclinical and clinical studies. The complexity of cancer research requires a multidisciplinary approach, and in vivo CROs are adept at providing the essential tools, expertise, and resources to accelerate the development of innovative therapies. As personalized medicine gains traction, tailoring treatments to individual genetic profiles necessitates sophisticated research techniques offered by these CROs. Moreover, the competition to bring novel therapies to the market drives the outsourcing trend, as companies seek to streamline operations and enhance efficiency. In a landscape characterized by rapid advancements in genomics, imaging technologies, and data analytics, in vivo CROs play an indispensable role in facilitating groundbreaking discoveries. Ultimately, the surging tide of cancer cases has not only heightened the demand for effective treatments but has also become a powerful catalyst for the expansion and diversification of the oncology based in vivo CRO market, propelling it into a pivotal position at the forefront of the fight against this formidable disease.

Advancements in Cancer Research

The ever-evolving landscape of cancer research is wielding a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. With each stride in our understanding of cancer biology, genetics, and treatment mechanisms, the demand for highly specialized research services provided by in vivo CROs surges. Advancements in areas such as immunotherapy, targeted therapies, and precision medicine have transformed the oncology field, necessitating more intricate and tailored studies. In vivo CROs possess the expertise and cutting-edge technologies required to conduct complex preclinical and clinical investigations that align with these breakthroughs. As new avenues for treatment emerge, pharmaceutical and biotechnology companies are increasingly turning to these CROs to expedite drug development processes and ensure the safety and efficacy of their therapies. The intricate interplay between genetics, tumor microenvironments, and therapeutic responses mandates a comprehensive and multidimensional approach to research, and in vivo CROs are poised to fulfill this role adeptly. Furthermore, the competitive drive to be at the forefront of innovative cancer treatments has spurred companies to outsource research activities to specialized partners, contributing to the expansion of the CRO market. In an era characterized by rapid scientific progress, the symbiotic relationship between advancements in cancer research and the growth of the oncology based in vivo CRO market is poised to forge a transformative path forward in the fight against cancer.

Key Market Challenges

Complexity of Cancer Research

The intricate nature of cancer research stands as a formidable obstacle impeding the growth of the oncology-based in vivo Contract Research Organization (CRO) market. The multifaceted challenges posed by the diversity of cancer types, intricate genetic variations, and evolving treatment paradigms demand a level of specialized expertise that few can provide. Conducting accurate and comprehensive in vivo studies that mirror the complex reality of cancer within living organisms requires sophisticated methodologies and equipment, which can strain the resources of both CROs and their clients. Moreover, the need to keep abreast of rapidly advancing scientific discoveries adds another layer of complexity. Ensuring that in vivo studies effectively capture the intricate interplay of genetic factors, tumor microenvironments, and treatment responses necessitates a multidimensional approach that requires not only cutting-edge technologies but also a deep understanding of cancer biology. As such, the complexity of cancer research can hinder the growth of the in vivo CRO market by limiting the pool of experts, increasing costs, and elongating project timelines, thereby underscoring the critical need for sustained innovation and collaboration within the field.

High Costs

The soaring costs associated with oncology-based in vivo Contract Research Organization (CRO) services pose a significant barrier to the market's expansion. Conducting comprehensive in vivo studies demands advanced equipment, skilled personnel, and substantial resources, resulting in elevated project costs. These expenses can deter smaller pharmaceutical and biotech companies, as well as research institutions with limited budgets, from accessing the expertise and services offered by in vivo CROs. Moreover, the high costs can also lead to increased pricing for services, potentially making them unaffordable for certain clients. This financial strain can curtail research and development efforts, slow down the pace of drug discovery, and limit the industry's ability to accommodate a broader range of projects. As such, addressing the issue of high costs is pivotal for fostering a more accessible and vibrant oncology based in vivo CRO market, enabling diverse entities to harness the specialized capabilities required to advance our understanding and treatment of cancer.

Key Market Trends

Personalized Medicine

The paradigm shift towards personalized medicine is exerting a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As medical science increasingly recognizes the unique genetic and molecular profiles that underlie individual patients' responses to treatments, the demand for highly tailored research and preclinical studies has surged. In vivo CROs are at the forefront of this transformative trend, enabling the creation of animal models that closely mimic patients' genetic characteristics. These models allow for precise evaluations of potential therapies, predicting their effectiveness and potential side effects in specific patient populations. The intricate interplay between genetic factors, tumor microenvironments, and treatment responses necessitates nuanced research methodologies, and in vivo CROs possess the expertise and cutting-edge technologies required to execute such studies. With the goal of developing treatments that are optimally effective and minimally toxic for each patient, pharmaceutical and biotech companies are increasingly relying on in vivo CROs to conduct studies that bridge the gap between preclinical research and clinical trials. As personalized medicine gains momentum, the strategic role of in vivo CROs in shaping the landscape of oncology research and therapy development becomes ever more pronounced, solidifying their pivotal contribution to the advancement of precision cancer care.

Digitalization and Data Analytics

The rapid integration of digitalization and data analytics is wielding a transformative impact on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As cancer research becomes increasingly data driven, in vivo CROs are leveraging advanced technologies to enhance the efficiency, accuracy, and depth of their studies. Real-time monitoring, high-resolution imaging, and sophisticated data analysis tools enable a comprehensive understanding of cancer biology, treatment responses, and disease progression. This digital revolution empowers researchers to extract meaningful insights from complex datasets, identifying subtle patterns and correlations that were previously elusive. In vivo CROs equipped with these capabilities can offer a comprehensive view of how potential therapies interact with living organisms at molecular and cellular levels, paving the way for more informed decision-making during drug development. Additionally, the integration of digital tools facilitates remote monitoring and collaboration, allowing researchers to conduct studies across geographical boundaries. This not only accelerates research timelines but also opens doors to global partnerships and client collaborations. As the demand for precise and data-rich insights in oncology research intensifies, in vivo CROs adept in harnessing digitalization and data analytics are poised to drive advancements in our understanding of cancer and propel the development of more effective therapies, solidifying their pivotal role in the dynamic landscape of oncology research.

Segmental Insights

Indication Insights

With a 47.08% market share in 2022, the solid tumors segment dominates the Oncology Based In-vivo CRO market and is predicted to continue expanding over the coming years. Solid tumors have emerged as dominant players in the oncology-based in vivo Contract Research Organization (CRO) market due to their prevalence and complex nature. These tumors, characterized by their cohesive mass of cells, represent a significant portion of cancer cases, driving the demand for specialized research services provided by in vivo CROs. Given the intricate interplay of genetic mutations, microenvironmental factors, and treatment responses within solid tumors, preclinical studies conducted by in vivo CROs are essential for evaluating potential therapies. As the understanding of solid tumor biology and targeted therapies advances, pharmaceutical and biotech companies increasingly rely on these CROs to conduct comprehensive studies that inform clinical trial design and decision-making. The specialized expertise of in vivo CROs in creating accurate animal models and conducting sophisticated analyses aligns with the intricacies of solid tumor research, establishing them as pivotal contributors in advancing our ability to combat these formidable diseases.

Model Insights

In 2022, the Oncology Based In-vivo CRO market was dominated by the Syngeneic segment, which held the largest revenue share of 70.82%. Syngeneic models have surged to dominance in the oncology-based in vivo Contract Research Organization (CRO) market due to their exceptional relevance and utility in cancer research. These models involve transplanting tumor cells into animals with intact immune systems from the same species, enabling the study of tumor-immune interactions and the evaluation of immunotherapies. This approach more accurately mirrors the complex dynamics of human immune responses to tumors. As immunotherapy gains traction as a groundbreaking avenue for cancer treatment, pharmaceutical and biotech companies seek in vivo CROs with specialized expertise in syngeneic models. These CROs offer the capacity to assess the efficacy and safety of novel immunotherapies, predict potential side effects, and optimize treatment strategies. By closely replicating the human immune system's responses to tumors, syngeneic models are playing a pivotal role in advancing immunotherapy research and shaping the trajectory of oncology based CRO services.

Regional Insights

The North America region has established itself as the leader in the Oncology Based In-vivo CRO Market with a significant revenue share of 37% in 2022.

Key Market Players

Charles River Laboratories, Inc.

ICON PLC

Thermo Fisher Scientific Inc.

Eurofins Scientific SE

Taconic Biosciences, Inc.

Crown Biosciene, Inc.

LabCorp

WuXi AppTec Co., Ltd.

Evotec SE

The Jackson Laboratory

Report Scope:

In this report, the Oncology Based In-vivo CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Based In-vivo CRO Market, By Indication:

Blood Cancer
Solid Tumor

Oncology Based In-vivo CRO Market, By Model:

Syngeneic Model
Patient Derived Xenograft
Xenograft

Oncology Based In-vivo CRO Market, By Region:

North America
Europe
South America
Asia Pacific
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Oncology Based In-vivo CRO Market.

Available Customizations:

Oncology Based In-vivo CRO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Based In-vivo CRO Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Indication (Blood Cancer, Solid Tumor)
- 5.2.2. By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Market Map

6. North America Oncology Based In-vivo CRO Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Indication
- 6.2.2. By Model
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Oncology Based In-vivo CRO Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Indication
    - 6.3.1.2.2. By Model
- 6.3.2. Canada Oncology Based In-vivo CRO Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Indication
    - 6.3.2.2.2. By Model
- 6.3.3. Mexico Oncology Based In-vivo CRO Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Indication
    - 6.3.3.2.2. By Model

7. Europe Oncology Based In-vivo CRO Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Model
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Oncology Based In-vivo CRO Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Indication
    - 7.3.1.2.2. By Model
- 7.3.2. United Kingdom Oncology Based In-vivo CRO Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Indication
    - 7.3.2.2.2. By Model
- 7.3.3. Italy Oncology Based In-vivo CRO Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Indication
    - 7.3.3.2.2. By Model
- 7.3.4. France Oncology Based In-vivo CRO Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Indication
    - 7.3.4.2.2. By Model
- 7.3.5. Spain Oncology Based In-vivo CRO Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Indication
    - 7.3.5.2.2. By Model

8. Asia-Pacific Oncology Based In-vivo CRO Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Model
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Oncology Based In-vivo CRO Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Indication
    - 8.3.1.2.2. By Model
- 8.3.2. India Oncology Based In-vivo CRO Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Indication
    - 8.3.2.2.2. By Model
- 8.3.3. Japan Oncology Based In-vivo CRO Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Indication
    - 8.3.3.2.2. By Model
- 8.3.4. South Korea Oncology Based In-vivo CRO Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Indication
    - 8.3.4.2.2. By Model
- 8.3.5. Australia Oncology Based In-vivo CRO Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Indication
    - 8.3.5.2.2. By Model

9. South America Oncology Based In-vivo CRO Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Model
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Oncology Based In-vivo CRO Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Indication
    - 9.3.1.2.2. By Model
- 9.3.2. Argentina Oncology Based In-vivo CRO Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Indication
    - 9.3.2.2.2. By Model
- 9.3.3. Colombia Oncology Based In-vivo CRO Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Indication
    - 9.3.3.2.2. By Model

10. Middle East and Africa Oncology Based In-vivo CRO Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Model
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Oncology Based In-vivo CRO Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Indication
    - 10.3.1.2.2. By Model
- 10.3.2. Saudi Arabia Oncology Based In-vivo CRO Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Indication
    - 10.3.2.2.2. By Model
- 10.3.3. UAE Oncology Based In-vivo CRO Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Indication
    - 10.3.3.2.2. By Model

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Treatment Type Launches

13. Global Oncology Based In-vivo CRO Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

15.1. Business Overview
15.2. Service Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
- 15.5.1. Charles River Laboratories, Inc.
- 15.5.2. ICON PLC
- 15.5.3. Thermo Fisher Scientific Inc.
- 15.5.4. Eurofins Scientific SE
- 15.5.5. Taconic Biosciences, Inc.
- 15.5.6. Crown Biosciene, Inc.
- 15.5.7. LabCorp
- 15.5.8. WuXi AppTec Co., Ltd.
- 15.5.9. Evotec SE
- 15.5.10. The Jackson Laboratory